MYOK

Submission status for MYOKARDIA INC's drug CAMZYOS (ORIG-1) with active ingredient MAVACAMTEN has changed to 'Approval' on 04/28/2022. Application Category: NDA, Application Number: 214998, Application Classification: Type 1 - New Molecular Entity

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with Markers of HCM Severity in Non-Obstructive HCM Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy (HCM), at the America

BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. The registry will support MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, an investigational therapeutic for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The newly established mavacamten long-term safety registry will utilize the PINNACLE Registry, the largest out-patient car

BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program Highlights Mavacamten for Hypertrophic Cardiomyopathy (HCM) EXPLORER-HCM Data Presented at the European Society of Cardiology 2020 Virtual Congress and Published in The Lancet: Results from MyoKardia’s Phase 3 clinical study of mavacamten for the potential treatment of symptomatic, obstructive HCM demonstrated statistically significant improvements in patient symptoms and cardiac function, as well as reductions in left ventricular outflow tract (LVOT) obstruction. In addition to meeting the primary and

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2020, which reflect strong product sales, continued pipeline advancement and robust operating performance. “I am proud of the significant achievements of our new company over the past year, and the strong foundation we have created for near- and long-term growth” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “Our financial strength and flexibility combined with our robust inline businesses, multiple launches and progress in our deep pipeline, including the promising results from the deucravacitinib trial, strongly position the compa

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia’s mission to promote understanding and treatment of the underlying drivers of serious cardiovascular diseases.  More than 50 applicants submitted proposals, which were assessed for scientific merit, feasibility and impact of the proposed project, and alignment with the research priorities for the funding cycle. This year’

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020. Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction, which remains subject

BRISBANE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy, at the upcoming American Heart Association’s Scientific Sessions 2020. Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten. These data are expected to build on the previously published safety and efficacy results from the Phase 3 clinical study by providing ad

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Montage Resources Corporation (NYSE: MR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Southwestern Energy Company. If you are a Montage shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/montage-resources-corporation-mr-stock-merger-southwestern/. MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] MyoKardia, Inc. (NASDAQ: MYOK) – URGENT – TENDER OFFER EXPIRES NOVEMBER 16, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. (NASDAQ: MYOK) in connection with the proposed acquisition of the company by Bristol-Myers Squibb Company.  Under the terms of

NEW YORK, Oct. 23, 2020 /PRNewswire/ -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. BMC Stock Holdings, Inc. (NASDAQ: BMCH) - Builders FirstSource, Inc. (NASDAQ: BLDR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the

NEW YORK, Oct. 22, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] MyoKardia, Inc. (NASDAQ: MYOK) – URGENT – TENDER OFFER EXPIRES NOVEMBER 16, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. (NASDAQ: MYOK) in connection with the proposed acquisition of the company by Bristol-Myers Squibb Company.  Under the terms of

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: MyoKardia, Inc. (NASDAQ: MYOK) MyoKardia has agreed to be acquired by Bristol-Myers Squibb. Under the proposed transaction, shareholders of MyoKardia will receive $225.00 in cash per share owned. BioSpecifics Technologies Corp. (NASDAQ: BSTC) BioSpecifics Technologies has agree

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $225.50 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/. Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc.  Under the merger agree

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Eaton Vance Corp. (NYSE: EV) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eaton Vance Corp. (NYSE: EV) in connection with the proposed acquisition of the company by Morgan Stanley.  Under the terms of the acquisition agreement, EV shareholders will receive $28.25 cash

NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Montage Resources Corporation (NYSE: MR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MR to Southwestern Energy Company. If you are a MR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. MyoKardia, Inc. (NASDAQ: MYOK) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MYOK to Bristol-Myers Squibb for $225.00 per share. If you are a MYOK

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. BMC Stock Holdings, Inc. (NASDAQ: BMCH) - Builders FirstSource, Inc. (NASDAQ: BLDR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the

NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: American Renal Associates Holdings, Inc. (NYSE: ARA) American Renal Associates Holdings has agreed to be acquired by affiliates of Nautic Partners.  Under the proposed transaction, shareholders of American Renal will receive $11.50 in cash for every share owned. Eidos T

NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $225.50 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/. Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc.  Under the merger agreement, Eidos st

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. ("MYOK" or the "Company") (NASDAQ: MYOK) in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company ("Bristol Myers").  Under the terms of the acquisition agreement, which is structured as a tender offer, MYOK shareholders will be entitled to receive $225.00 in cash for each share of MYOK common stock that they own. If you own MYOK shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.we

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 per share in cash is fair to MyoKardia shareholders. On behalf of MyoKardia shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are a MyoKardia shareholder and would like to discuss your legal rights and options, visit MyoKardia Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The i

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of MyoKardia, Inc. (NASDAQ: MYOK) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Bristol Myers Squibb (NYSE: BMY). Click here to learn more and participate in the action. On October 5, 2020, MyoKardia announced that it had signed an agreement to be acquired by Bristol Myers Squibb for approximately $13.1 billion. Pursuant to the merger agreement, MyoKardia stockholders will receive $225 in cash for each share of MyoKardia common stock

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc. ("MyoKardia" or the "Company") (NASDAQ: MYOK) breached their fiduciary duties in connection with the proposed sale of the Company to Bristol Myers Squibb (NYSE: BMY).  On October 5, 2020, MyoKardia announced that it had entered into a definitive merger agreement with Bristol Myers Squibb. Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will acquire all of the outstanding shares of MyoKardia's common stock for $225.00 per share in cash. The investigation concerns whether the MyoKardia board fai

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020. MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiov